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ABSTRACT
Objective: We have shown that one treatment of fever-like whole body hyperthermia (WBH) on
mice bearing human breast tumors results in a tumor growth delay. Our goal was to repeat this
study in mice bearing human ovarian or colon tumors. We further evaluated thisWBH protocol by
performing multiple and interrupted WBH treatments.
Methods: Human tumors were grown in severe combined immunodeficient (SCID) mice. For
WBH, core body temperatures were maintained at 39.8+0.2C for 6-8 hours. Multiple treatments
were given 6-7 days apart. InterruptedWBH consisted of three 2-hour heatings, 15 minutes apart.
Tumor growth time (TGT) was the number of days to grow 1.5 or 2 times in volume.
Results: For WBH-treated ovarian tumors, TGT was 12+1.2d, compared with 5.0+0.1d for
untreated mice (P < 0.05). For colon tumors with oneWBH treatmentTGT was 4.4+ 1.1d. Two and
three treatments had TGTs of 9+2.3d and 8+1.6d. For the untreated tumors, TGT was 2+0.7d
(P < 0.01 for one, two, and three treatments). Histological examination indicated that one and two
treatments were associated with cellular damage within the tumors. With a slower growing colon
tumor, the TGT was 24+3.3d with three WBH treatments, compared with 14+1.8d for controls
(P < 0.01). The TGT of breast tumors treated with interruptedWBH was not significantly different
than the noninterrupted, with TGT of 7.3+0.8d and 6.2+1.0d, respectively.
Conclusions: These data illustrate thatWBH causes a tumor growth delay in mice bearing human
ovarian and colon tumors. This response is enhanced with a second treatment ofWBH. Interrupted
and noninterrupted WBH give comparable anti-tumor results. We will continue to evaluate WBH
in various animal models to optimize its potential for clinical administration and maximize the
anti-tumor response. Infect. Dis. Obstet. Gynecol. 7:91-97, 1999. (C) 1999 Wiley-Liss, Inc.
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or many solid tumors, it is possible to control
the initial malignancy with surgical excision.
Unfortunately, surgical methods are not as success-
ful if the cancer recurs or spreads to other sites in
the body. Although there are already systematic
treatments, such as chemotherapy, applied to most
patients as follow up to surgery, it is evident that
only a small fraction of patients actually benefit
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from this treatment in terms of overall survival.
The goal of our laboratory is to develop better
therapies to enhance a patient’s own immune re-
sponse against his or her tumor; these therapies
may be useful alone or as an adjuvant therapy in
combination with chemotherapy or radiation. A
large part of our effort is being devoted to the ex-
amination of mild, long-duration (fever-like)
whole-body hyperthermia (WBH) as a possible
means to help stimulate the immune system.
1-3
When clinical hyperthermia was first conceived
for use in cancer treatment, it was envisioned as a
type of thermal radiation therapy whereby a heat
treatment sufficient to sterilize or directly kill can-
cer cells would selectively be delivered to the tu-
mor. It has been noted in the past few years, how-
ever, that the tumor temperatures achieved during
these local treatments were well below those
known to be cytotoxic.
4-6 Whole-body hyperther-
mia protocols have been developed that have em-
ployed temperatures as high as 42C given for du-
rations ranging from 15 min. to 2 hours.7-1’For the
studies described herein, we utilized a mild (fever-
like) WBH protocol in which the core body tem-
perature is maintained at 39.8C for 6-8 hours. ,3
This is similar to that obtained during a normal
febrile episode, and other work in our lab is de-
voted to determining what immunologicaleffector
activity is affected by the thermal element of fe-
ver.2,11,12
We have previously shown that a single treat-
ment of mild WBH caused a significant (albeit
temporary) reduction of tumor volume and a tumor
growth delay in severe combined immunodeficient
(SCID) mice bearing human breast xenografts and
Balb/c mice bearing transplantable, syngeneic tu-
mors. The anti-tumor effect seen with the treat-
ment was correlated with the appearance of large
numbers of apoptotic tumor cells and an increase in
the size of intratumor blood vessels. Substantial
levels of several heat shock proteins (Hsps), includ-
ing HspT0 and Hspll0, are also induced in the
tumor, lz Increased numbers of granulocytes, mac-
rophages, and lymphocytes were also observed in
the tumor vasculature and in the tumor stroma im-
mediately following WBH exposure. Our labora-
tory has also shown that WBH results in several
changes in tissue lymphocytes indicative of altered
activation levels. These include the alterations in
cellular and subcellular proteins, adhesion, and the
induction of Hsps.z,l’e These data provide evi-
dence that there may in fact be an enhancement of
the immune system with mild WBH. It is likely
that these alterations in structure and function of
immune cells that we have recognized are associ-
ated with the tumor killing we have observed.
In this paper, we describe experiments to fur-
ther characterize this fever-like WBH protocol. We
have expanded our studies to include human ovar-
ian and colon tumor xenografts. We have investi-
gated the potential to enhance the observed anti-
tumor response with additional treatments of
WBH. Lastly, we have altered the protocol to give
WBH in two short increments, instead of one long
treatment, so that it may be more clinically toler-
able.
SUBJECTS AND METHODS
Tumor Implantation and Growth
Human ovarian (#8436), colon (#9427), and breast
(#8600) tumor surgical specimens were received
from the Roswell Park Cancer Institute Tissue Pro-
curement Facility (Buffalo, NY). These tissues
were implanted subcutaneously into 8-week old fe-
male c.b.17 scid/scid mice from Taconic Laborato-
ries (Germantown, PA). These tumors were pas-
saged several times in SCID mice and dissected
into pieces 2 mm in diameter, which were im-
planted subcutaneously into SCID mice for use in
these experiments. After the tumors reached a vol-
ume of approximately 60mm, WBH was initiated.
The tumors were measured with a vernier caliper
every 2 days to determine the shortest diameter (A)
and the longest diameter (B). The volume was
then calculated by using the formula V (AZB)/2.
The relative tumor growth (Tr) was then calculated
for each tumor by dividing the volume at any given
day after WBH (To) by the volume at the start of
WBH (To).
WBH Treatment
Mice were placed in microisolater cages preheated
to 39C that contained food, bedding, and water; it
is important that the water was at least 39C. The
cages were then placed in a gravity convection
oven (Memmert model BES00, East Troy, WI)
with preheated incoming fresh air. The average
body temperature of the mice before WBH was
37.5C. The body temperature was gradually in-
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Fig. I. Effect of WBH on the growth of human ovarian tumor #8436. SCID mice bearing a human ovarian tumor were
treated with WBH for 6 hours on day 0. Tumors were measured with calipers every other day and relative tumor volume
was calculated and graphed vs. days post-WBH (see "Materials and Methods’). In the control group (a; n 5), TGT was 5.0
+_ O. d. In the WBH treated group (b; n 5), TGT was 12.0 + 1.2d (P < 0.05 when compared with the control; Student test).
creased 1C every 30 minutes until a core tempera-
ture of 39.8C (+0.2C) was achieved. The tem-
perature of the incubator was adjusted when nec-
essary to maintain a constant core temperature of
39.8C for 6-8 hours. For some experiments, the
6-8 hour heating was repeated three times every
6-7 days. In other experiments, this heating proto-
col was altered such that the mice were taken out
of the incubator after 3 hours of heating at 39.8C
and remained at room temperature for 15 minutes.
The mice then were returned to the incubator to
receive another 3 hours of heating at 39.8C. Dur-
ing WBH, the core temperatures of the mice were
monitored with the Electric Laboratory Animal
Monitoring System Pocket Scanner (model 5007)
from Biomedic Data Systems (Maywood, NJ). Mi-
crochip transponders (14 mm 2.2 ram) were sub-
cutaneously implanted into the dorsal thoracic area
with a trocar into nonexperimental animals. These
animals were placed in cages with their experimen-
tal animal counterparts at least 24 hours prior to the
initiation of the WBH treatment. Temperatures
were collected using the pocket scanner, which has
a liquid-crystal display screen where the tempera-
ture information is displayed. We found that it was
not difficult to maintain body temperature be-
tween 39C and 40C. When heating several ani-
mals, internal variability between individual ani-
mals was +0.2C.
After the WBH treatment, animals were placed
back in their regular cages. In some experiments, a
representative animal from each group was sacri-
ficed 8 hours after the WBH treatment to examine
the histology of the tumors. Tumor measurements
were taken as described above for the remainder of
the experiment.
Statistical Analysis of Data
Tumor growth time (TGT), or time for the tumor
volume to reach 1.S times (for the ovarian and co-
lon tumor experiments) or 2 times (for the breast
tumor experiments) its original tumor volume was
calculated in days. A Student t test was performed
to compare TGT values for WBH treated mice
with those for control mice.
RESULTS
Effects of WBH on SCID Mice Bearing Human
Ovarian Tumors
Whole-body hyperthermia was effective in exert-
ing an anti-tumor response on SCID mice bearing
human ovarian tumors (Fig. 1). The TGT for this
experiment was the number of days for the tumor
to reach 1.S times its original volume. The TGT of
the unheated control tumors for this experiment
was as S.0 + 0.1d. The TGT of the WBH-treated
tumor was 12+1.2d (P < 0.05). These results are
comparable to our previous data using human
breast tumors.
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Fig. 2a. Effect of multiple WBH treatments on a fast-growing human colon tumor #9427. SCID mice bearing a human colon
tumor were treated with WBH for 6 hours on days 0, 5, and II. Tumors were measured with calipers regularly for the
duration of the experiment. Relative tumor volume was calculated and graphed vs. days. Control, n 4; WBH Ix, n 4; WBH
2x, n=4;WBH 3x, n=4.
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Fig. 2b. Time for tumor to reach 1.5x original volume (TGT). TGTs were calculated for each treatment group from the mice
in Fig. 2a. In mice with colon tumors receiving oneWBH treatment, TGT was 4.4 + I. d. Those with two and three treatments
had TGTs of 9.0 + 2.3d and 8.0 + 1.6 days. For the untreated tumors, TGT was 2.0 + 0.7d (P < 0.01 for one, two, and three
treatments when compared with the control; Student test).
Effects of Single and Multiple Treatments of
WBH on Mice Bearing a Fast-Growing and a
Slow-Growing Variant of a Human
Colon Tumor
To investigate the effects of WBH on fast- and
slow-growing tumors, we utilized a colon tumor
that has both a fast- and slow-growing variant. The
tumors in the mice bearing the fast-growing variant
of a human colon tumor responded to WBH (Fig.
2a). The TGT for this tumor was the number of
days for the tumor to reach 1.5 times its original
volume. The control TGT was 2 + 0.7d. The TGT
for the tumors treated one time with WBH was 4.4
+ 1.1d (P < 0.01). Those that were given a second
treatment also responded to hyperthermia, and the
anti-tumor response was greater (TGT was 9 _+
2.3d, P < 0.01 when compared with the control).
For the mice that were given a third treatment, the
response was not significantly different when com-
pared with those that received two treatments
(TGT was 8 _+ 1.6 days, P < 0.01when compared
with control) (Fig. 2b). Histological examination of














Fig. 3. Effect of multipleWBH treatments on the growth of a slow-growing colon tumor #9427. SCID mice bearing a human
colon tumor were treated with three doses ofWBH for 6 hours on days 0, 7, and 14. Tumors were measured with calipers
regularly for the duration of the experiment. Relative tumor volume was calculated and graphed vs. days. In the control group
(a; n 7), TGT was 14.3 + 1.8d. In the WBH 3x group (b; n 7), TGT was 25.0 + 3.3d. (P < 0.01 when compared with the
control).
the tumors indicated that the first and second treat-
ments of hyperthermia were associated with
changes indicative of cellular damage; following a
third treatment, tumor structure was comparable to
the nonheated control (data not shown). The in-
duction of Hsp70 and Hspll0 was also seen in
these tumors following WBH (data not shown).
The extent of the anti-tumor responses that have
been observed differ from tumor to tumor. For ex-
ample, when tumor growth was evaluated for a
slow-growing variant of the same human colon tu-
mor the TGT was 25 _+ 3.3d. When WBH was
administered, the TGT was 14.3 _+ 1.8d, P < 0.01
(Fig. 3). For the fast-growing variant, the time to
reach 1.5 times the original volume was increased
by 300% with the treatment. Whole-body hyper-
thermia on the slow-growing tumor increased the
TGT by 108%.
Effects of Interrupted WBH on SCID Mice
Bearing Human Breast Tumors
Uninterrupted and interrupted WBH treatments
were very similar with regard to the tumor growth
delay (Fig. 4). Due to the rapid growth rate of this
tumor, TGT was the time for tumor volume to
double. For the control tumor, the TGT was 3.0 _+
0.1d. The interrupted and uninterrupted treat-
ments had TGTs of 7.3 +_ 0.8d and 6.2 _+ 1.0d,
respectively (P < 0.01, P < 0.01 when compared
with control). There was no statistical difference
between the interrupted and continual WBH treat-
ments.
DISCUSSION
We have repeatedly observed that fever-like WBH
exerts an anti-tumor effect on the growth ofhuman
tumors in SCID mice. Human breast, ovarian, and
colon tumors respond to this therapy in a similar
manner, indicating that the temporary tumor
growth delay is most likely not tumor specific. The
extent of this response, however, does show some
variation between tumors. This difference could be
attributed to inherent differences between tumors.
This data is highly suggestive that applications of
this mild WBH protocol in a clinical setting may be
beneficial to patients. Although the result is tem-
porary, it may be enough to give an advantage to
current strategies, such as chemotherapy or radia-
tion therapy, which are not always as effective as
one would hope. Also, many of these regimens ex-
ert toxic side effects at the high doses necessary for
success; perhaps WBH could act as an adjuvant to
allow these therapies to be given at less toxic doses
that would still be effective. Moreover; since our
data indicate that WBH is most likely immuno-
stimulatory, combining hyperthermia with differ-
ent types of immunotherpy, such as cytokine
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Fig. 4. Effect of continual and interrupted WBH on the growth of a human breast tumor #8600. SCID mice bearing a human
breast tumor were treated with WBH on day 0 for 6 hours (continual WBH, n 9) or for 3 hours with a 15-minute break
and continuing with another 3 hours for a total of 6 hours (interrupted WBH, n 5). In the control group (a), TGT was 3.0
+ O.01d. In the continual WBH group (b), TGT was 7.3 + 0.8d (P < 0.01 when compared with the control). In the interrupted
WBH group (c), TGT was 6.2 + 1.0d (P < 0.01 when compared with the control).
therapy or gene therapy, may prove to be even
more successful.
Although combining WBH with other therapies
is an ultimate goal, we are continually reexamining
the effects of this model alone in order to obtain
the greatest possible anti-tumor response. Thus far,
our data has shown that 6 hours ofWBH will give
this maximum response. Interestingly, this treat-
ment can be given in one long administration or in
interrupted treatments. The interrupted WBH de-
sign could prove to be a more comfortable alterna-
tive to patients undergoing WBH. We have also
shown that a second 6-hour WBH treatment ap-
pears to enhance the anti-tumor response observed
with one treatment. However, for at least one
model, a third WBH exhibited no apparent advan-
tage over two treatments. Our laboratory is cur-
rently investigating possible reasons for this lack of
efficacy. We speculate that thermotolerance may
have a role; some permanent change in tumor
structure may occur with the first and second treat-
ments that result in the loss of response to more
heat.
Current studies are also underway to demon-
strate interdependence between the anti-tumor re-
sponse seen with WBH and the changes our stud-
ies have shown on both lymphocytes and tumor
cells. We have hypothesized that simple mild hy-
perthermia treatment may have the ability to acti-
vate antigen-independent pathways that result in
enhanced lymphocyte polarity and adhesion. This
in turn may facilitate subsequent antigen-depen-
dent immune events. It is tempting to speculate
that these same alterations may also occur during
an actual fever following infection or other pertur-
bations of the immune system. Since our data also
indicate that even those mild WBH protocols can
induce Hsps, we are very interested in determining
what their role may be in stimulating the immune
response.
A phase-I WBH clinical protocol has recently
begun at Roswell Park Cancer Institute (under the
direction of W. Kraybill, MD, Department of Sur-
gery). It was designed to evaluate the safety and
immunological effects of fever-like WBH alone in
patients with advanced cancer. We will also con-
tinue to evaluate this fever-like WBH model pre-
clinically in animal models. An understanding of
the immune mechanisms that may be enhanced
and their possible role in the anti-tumor response
seen with WBH could lead to the development of
novel therapies in the treatment of human breast,
ovarian, and colon cancers.
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